News & Updates

Statins may protect the heart from chemo for breast cancer

07 Jan 2021 by

Women who received statins were less likely than those who did not to have ED* visits or hospitalizations for heart failure (HHF) following chemotherapy with anthracyclines for early breast cancer (EBC) — suggesting that statins may protect the heart against damage induced by chemotherapy, at least among older women.

Statins may protect the heart from chemo for breast cancer

07 Jan 2021

Which tool is best for screening interactions between herbal supplements, anticancer agents?

07 Jan 2021

The best available tool for detecting herb–drug interaction is Lexicomp, and the best free alternative is Medscape, suggests a study. However, the sensitivity and performance for detecting herb–drug interaction is far lower than for drug–drug interactions and quite poor overall.

Which tool is best for screening interactions between herbal supplements, anticancer agents?

07 Jan 2021

First-line lorlatinib trumps crizotinib for advanced ALK+ lung cancer

07 Jan 2021 by

The novel third-generation ALK* inhibitor lorlatinib outdid the first-generation inhibitor crizotinib as treatment for previously untreated advanced ALK+ non-small-cell lung cancer (NSCLC), according to the interim results of the CROWN trial.

First-line lorlatinib trumps crizotinib for advanced ALK+ lung cancer

07 Jan 2021

Tenofovir prodrug for CHB on par with tenofovir disoproxil fumarate

07 Jan 2021

HS-10234, a novel tenofovir prodrug, is well-tolerated and as potent as tenofovir disoproxil fumarate (TDF) in the treatment of patients with chronic hepatitis B (CHB) infection, according to the results of a phase Ib trial.

Tenofovir prodrug for CHB on par with tenofovir disoproxil fumarate

07 Jan 2021

Two-year maintenance olaparib could reduce ovarian cancer recurrence risk

06 Jan 2021 by

Two years of maintenance olaparib reduces recurrence risk in women with newly diagnosed advanced ovarian cancer with BRCA mutation (BRCAm), according to long-term results of the SOLO1* trial.

Two-year maintenance olaparib could reduce ovarian cancer recurrence risk

06 Jan 2021

Managing paediatric eczema in primary care

06 Jan 2021

There is a high burden of paediatric eczema in the primary care setting. Dr Liew Hui Min, a consultant dermatologist from SOG-HM Liew Skin & Laser Clinic at Gleneagles Hospital, Singapore, shares her insights with Pearl Toh on how to manage paediatric eczema in the primary care setting.

Managing paediatric eczema in primary care

06 Jan 2021

Tacrolimus more tolerable than cyclosporine in renal transplant patients

06 Jan 2021 by

Short-term renal transplant outcomes on patient survival, graft survival and function, and rejection rates are comparable between tacrolimus and cyclosporine, a Singapore study has found. Tacrolimus also appears more tolerable but is associated with opportunistic and more severe infections.

Tacrolimus more tolerable than cyclosporine in renal transplant patients

06 Jan 2021

Blinatumomab continues to prevail over CT for ALL

06 Jan 2021 by

Two trials presented at ASH 2020 reflect the immuno-oncotherapeutic benefit of the BiTE®* molecule blinatumomab in children with B-cell precursor acute lymphoblastic leukaemia (BCP-ALL).

Blinatumomab continues to prevail over CT for ALL

06 Jan 2021

ICS use in COPD, asthma does not affect COVID-19-related mortality

05 Jan 2021 by

Regular use of inhaled corticosteroids (ICS) for the treatment of chronic obstructive pulmonary disease (COPD) or asthma does not appear to affect COVID-19-related mortality, an observational study from England showed.

ICS use in COPD, asthma does not affect COVID-19-related mortality

05 Jan 2021

Reduced pegfilgrastim dose lowers neutropaenia-related events in breast cancer patients

05 Jan 2021

A reduction in pegfilgrastim doses among patients on myelosuppressive chemotherapy for breast cancer leads to a low incidence of neutropaenia-related events, including febrile and grade 3/4 neutropaenia, suggests a study.

Reduced pegfilgrastim dose lowers neutropaenia-related events in breast cancer patients

05 Jan 2021

News & Updates

Filter by Specialty:

Specialty:

Statins may protect the heart from chemo for breast cancer

Statins may protect the heart from chemo for breast cancer

Which tool is best for screening interactions between herbal supplements, anticancer agents?

Which tool is best for screening interactions between herbal supplements, anticancer agents?

First-line lorlatinib trumps crizotinib for advanced ALK+ lung cancer

First-line lorlatinib trumps crizotinib for advanced ALK+ lung cancer

Tenofovir prodrug for CHB on par with tenofovir disoproxil fumarate

Tenofovir prodrug for CHB on par with tenofovir disoproxil fumarate

Two-year maintenance olaparib could reduce ovarian cancer recurrence risk

Two-year maintenance olaparib could reduce ovarian cancer recurrence risk

Managing paediatric eczema in primary care

Managing paediatric eczema in primary care

Tacrolimus more tolerable than cyclosporine in renal transplant patients

Tacrolimus more tolerable than cyclosporine in renal transplant patients

Blinatumomab continues to prevail over CT for ALL

Blinatumomab continues to prevail over CT for ALL

ICS use in COPD, asthma does not affect COVID-19-related mortality

ICS use in COPD, asthma does not affect COVID-19-related mortality

Reduced pegfilgrastim dose lowers neutropaenia-related events in breast cancer patients

Reduced pegfilgrastim dose lowers neutropaenia-related events in breast cancer patients